WASHINGTON DC—A new blood test has detected drug-resistant mutations reliably in patients with gastrointestinal stromal tumour (GIST) helping to guide therapy when first-line drugs had failed. This wa
WASHINGTON DC—A new blood test has detected drug-resistant mutations reliably in patients with gastrointestinal stromal tumour (GIST) helping to guide therapy when first-line drugs had failed. This was in a study using the recently approved agent regorafenib. Dr George Demetri of the Dana-Farber Harvard Cancer Center presented findings from the GRID study during the 2013 conference of the American Society for Cancer Research. He told Peter Goodwin why the blood test did better than biopsy testing and about the prospects of treating refractory GIST with rogarafenib.